Figure 2
From: Plasma androgen receptor and serum chromogranin A in advanced prostate cancer
Survival in patients treated with abiraterone or enzalutamide by AR status and CgA levels in the Secondary cohort. PFS (A) and OS (B) in AR-normal and PFS (C) and OS (D) in AR-gained patients according to three different CgA level groups. The blue line is for patients with serum CGA <120 ng/mL, the orange line for CGA between 120 and 360 ng/mL, and the green line for CGA level >360 ng/mL.
